Relafen 750, identified as naproxen, represents a fascinating case study for biochemical pharmacy. Its mechanism of action entails the blocking of cyclooxygenase catalysts , specifically COX-1 and COX-2, ultimately diminishing prostaglandin synthesis . Examining the complex interplay between Relafen 750 and these enzymatic pathways provides valuabl